Issuu on Google+

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

The Non-small Cell Lung Cancer Drug Market in Indonesia Published on March 2012

Report Summary This research service presents an overview and analysis of the non-small cell lung cancer drug market in Indonesia from 2010 to 2015. It provides an analysis of the patient load, typical treatment regimens, clinical trial statistics, and treatment challenges. Along with this coverage, the research service also outlines market drivers and restraints, market engineering measurements, and market trends. The research service ends with a market analysis, which includes the competitive structure, and industry megatrends. Primary interviews were conducted with Indonesia's key opinion leaders in medical oncology and pulmonology, the National Cancer Center, and manufacturers, in order to obtain insight into the market landscape and market trends. Executive Summary Market Overview 'As of 2009, xx.x percent of the total population did not have health insurance. Those covered are mostly protected by basic government insurance schemes, offered to government employees and xx.x million poor and near-poor people. 'Of the xx.x percent of the population working in the private sector, only xx.x percent have health insurance. 'There is a lack of accurate and consistent data on prevalence, incidence and mortality for Indonesia. At the time of this study, the most recent data available on incidence and mortality is from the WHO global cancer study in 2008. 'Upon discussion with the Dharmais Cancer Center (National Cancer Center), it is confirmed that the WHO numbers may be an underestimate, considering the total population of xxx.x million, of which xx.x percent of adult males smoke. 'The development of the national cancer registry is in its inception stage, which could provide more accurate data in the future. 'Thus, patient analysis is based on primary research with medical specialists. 'In addition, market analysis in this study is based on sales of NSCLC drug cycles consumed by existing patients who can afford treatment. One cycle covers an average of x weeks of drug treatment for the patient. Patient Load and Forecast 'Most Non-small cell lung cancer (NSCLC) patients are diagnosed at the last two stages of the disease due to the innocuous symptoms of the early stages and a lack of comprehensive screening. 'In Indonesia, xx.x percent of NSCLC patients are diagnosed with stage III or IV, while the remaining xx.x percent are diagnosed with stage I or II. 'Wealthier patients leave for nearby countries, such as Singapore and Malaysia, for treatment. Indonesians contribute approximately $x.xx billion to medical tourism yearly. Market Forecast and Trends 'In 2010, NSCLC drug market in Indonesia totaled $xx.x million, with revenues projected to increase over the forecast period due to rising consumption and drug prices. 'xx.x percent of NSCLC drug revenue is from generics drugs, while xx.x percent is from branded. By the end of the forecast period, this ratio will reach xx.x percent generics and xx.x percent branded. 'The total number of NSCLC drug cycles, generic and branded, sold in 2010 was xx,xxx. Market Analysis 'The market revenue for generic and branded NSCLC drugs has been increasing primarily due to price increases. Analysis shows that the volume of branded cycles drop when the price-per- cycle of a branded NSCLC drug surpasses $xxx. 'With Indonesia being a price-sensitive market, lower-priced NSCLC generics have higher growth than branded generics. During the forecast period in this study, the price-per-cycle for generics is not estimated to reach the $xxx range, however, in the long run, it would be interesting to see how these two categories perform independently.

The Non-small Cell Lung Cancer Drug Market in Indonesia (From Issuu)

Page 1/4


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! 'Kalbe Farma, Ferron, and Combiphar, which sell generics, are the market leaders, occupying xx.x percent of the total market share. Roche, Sanofi Aventis, and AstraZeneca are fourth, fifth, and sixth and have x.x percent of the total market share.

Table of Content TABLE OF CONTENTS Executive Summary 4 Market Overview 12 Patient Load 24 Non-small Cell Lung Cancer Drug Market External Challenges: Drivers and Restraints'Non-small Cell Lung Cancer Drug Market 40 Forecast and Trends'Non-small Cell Lung Cancer Drug Market 50 Market Share and Competitive Analysis'Non-small Cell Lung Cancer Drug Market 61 Mega Trend impact and Industry Convergence Implications 70 The Last Word 73 Appendix 75

The Non-small Cell Lung Cancer Drug Market in Indonesia (From Issuu)

Page 2/4


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. The Non-small Cell Lung Cancer Drug Market in Indonesia

Product Formats Please select the product formats and the quantity you require. Site License--USD 6 000.00

Quantity: _____

Site License+Hardcopy--USD 6 500.00

Quantity: _____

Corporate License--USD 7 500.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

The Non-small Cell Lung Cancer Drug Market in Indonesia (From Issuu)

Page 3/4


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

 

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Asia, Oceania and America : + 1 (805) 617 17 93

The Non-small Cell Lung Cancer Drug Market in Indonesia (From Issuu)

Page 4/4


The Non-small Cell Lung Cancer Drug Market in Indonesia